4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Purpose Genetic testing has advanced significantly since the publication of the 2011
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Here we identify hundreds of new drug-disease associations for over 900 FDA-approved
drugs by quantifying the network proximity of disease genes and drug targets in the human …

Background Protection from lethal ventricular arrhythmias leading to sudden cardiac death
(SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic …

Pathogenic variants in the voltage-gated sodium channel gene family lead to early onset
epilepsies, neurodevelopmental disorders, skeletal muscle channelopathies, peripheral …

Forty per cent (40%) of sudden unexpected natural deaths in people under 35 years of age
are associated with a negative autopsy, and the cardiac ion channelopathies are the prime …

Abstract Aims Brugada syndrome (BrS) is associated with an increased risk of sudden
cardiac death due to ventricular tachycardia/fibrillation (VT/VF) in young, otherwise healthy …

Brugada syndrome (BrS) was first described as a primary electrical disorder predisposing to
the risk of sudden cardiac death and characterized by right precordial lead ST elevation …

Sudden cardiac death and ventricular arrhythmias are a global health issue. Recently, a
new guideline for the management of ventricular arrhythmias and prevention of sudden …